Promyelocytic leukemia (PML) protein is a tumor suppressor with complicated action mechanisms not yet fully understood. In this study, we found that the nuclear factor of activated T cell (NFAT) is an unexpected partner of PML: PML specifically enhanced the transcription activation of NFAT. In PML-null mouse embryonic fibroblasts, no transcription activity of NFAT could be detected. There was a selective requirement of PML isoform in NFAT activation: PML-I and PML-VI, but not PML-IV, increased NFAT transactivation. PML specifically promoted the expression of many, but not all, NFAT-targeted genes. We found a specific binding of PML to NFATc. The interaction of PML with NFATc in vivo was further confirmed by chromatin immunoprecipitation and DNA affinity precipitation assay analysis. The unexpected coupling of PML with NFAT reveals a novel mechanism underlying the diverse physiological functions of PML.
Introduction
Promyelocytic leukemia (PML) protein is a tumor suppressor that regulates cell growth, apoptosis, stress responses, antiviral reactivity and senescence (Salomoni and Pandolfi, 2002; Dellaire and Bazett-Jones, 2004) . PML is essential for the formation of PML nuclear bodies (also known as promyelocytic oncogenic domains (PODs), Kremer bodies), where Sp100, Daxx, p53, Rb, small ubiquitin-like modifier (SUMO-1) and breast cancer-1 (BRCA-1) are also located Dellaire and Bazett-Jones, 2004) . PML also acts as a cofactor for many transcription factors . Some of the transcription activities of PML are linked to the binding and recruitment of CREB-binding protein (CBP) or histone deacetylase to the PODs (Doucas et al., 1999; Wu et al., 2001) . Many PMLregulated transcription factors, including p53, c-Fos, Nur77, RelA, Myc and c-Jun, interact directly with PML Wu et al., 2002; Cairo et al., 2005; Salomoni et al., 2005) . Alternatively, for those transcription factors that do not bind to PML, such as glucocorticoid receptor and androgen receptor, their transactivation is enhanced through sequestration of the transcription repressor Daxx by PML (Li et al., 2000; Lin et al., 2003 Lin et al., , 2004 . PML gene contains nine exons. Alternative splicing results in at least seven isoforms of human PML, with different C-terminal sequences linked to the same N-terminal region containing really interesting new gene (RING) finger, B-boxes and coiled-coil domain (RBCC) region (Jensen et al., 2001; Condemine et al., 2006) . The functional specificities of the different PML isoforms remain incompletely understood.
The nuclear factor of activated T-cell (NFATs) family contains five transcription factor members: NFATc (NFAT2), NFATp (NFAT1), NFAT3, NFAT4 and NFAT5, which play key roles in the activation and differentiation in many different types of cells (Crabtree and Olson, 2002; Hogan et al., 2003) . An important step in the activation of NFATs is their dephosphorylation by calcineurin followed by translocation into nucleus (Crabtree and Olson, 2002) . In T cells, NFATp is immediately translocated into the nucleus after T-cell activation. T-cell activation also promotes the new synthesis of NFATc and its nuclear entry at the later phase of T-cell activation. In the nucleus, NFAT interacts with transcription co-activators including CBP and p300 for full transactivation (Garcia-Rodriguez and Rao, 1998; Avots et al., 1999; Wu et al., 2003a) . Many NFAT downstream targets have been identified, including IL-2 (interleukin-2), FasL, TNF-a (tumor necrosis factor), TRAIL (TNF-related apoptosis inducing ligand), Nur77 and Cbl-b (Tsai et al., 1996; Latinis et al., 1997; Wang et al., 2000; Youn et al., 2000; Macian et al., 2002) .
In this study, we found that PML is an essential partner for NFAT transactivation. NFAT was unable to activate selective promoter in the absence of PML. We further identified a specific interaction between PML and NFAT. The expression of many, but not all, NFAT-dependent genes required PML. Furthermore, PML is indispensable for the association of NFAT and CBP in TNF-a promoter. Our results suggest that NFAT mediates part of physiological functions of PML.
Results

PML stimulates NFAT but not NF-kB transactivation
Promyelocytic leukemia promoted the transactivation of NFAT. In the direct activation of NFAT-chloramphenicol acetyltransferase (CAT) by NFATc and NFATp, co-transfection with PML-VI greatly increased the transcription activation of NFAT-CAT in 293T cells (Figures 1a and b) . Similarly, NFATc-mediated activation of NFAT-CAT in EL4 T cells was largely enhanced by PML co-expression (Figure 1c) . The activation of NFAT-CAT by stimulation with TPA/A23187 in both Jurkat and EL4 T cells was also greatly augmented by PML-VI co-transfection (Figures 1e and f) . In contrast, nuclear factor-kB (NF-kB) p65-directed activation of kB-CAT in 293 cells was not increased by the presence of PML (Figure 1d ). Instead, PML co-transfection resulted in a weak but consistent decrease of kB-CAT in 293T cells. NF-kB p65-mediated activation of kB-CAT was similarly reduced in the presence of PML in Jurkat T cells (data not shown). Therefore, PML selectively augments the transactivation of NFAT.
Impaired NFAT transcription activity in PML-deficient MEFs
To further delineate the role of endogenous PML on NFAT transactivation, we used siRNA to downregulate PML in Jurkat cells. Different PML isoforms were expressed in Jurkat cells, and positions of PML-1, PML-IV and PML-VI on SDS-polyacrylamide gel electrophoresis were identified by their corresponding overexpression in 293 cells (Figure 2a) . Expression of PML-specific siRNA decreased all PML isoforms by the same extent (Figure 2a) . Knockdown of PML led to an inhibition in the activation of NFAT-CAT in Jurkat cells stimulated by TPA/A23187 ( Figure 2b ). As PMLspecific siRNA did not completely eliminate the expression of PML, PML-null mouse embryonic fibroblasts (MEFs) were used to further assess the role of PML in NFAT activation. In wild-type MEFs, transfection of either NFATc or NFATp significantly increased the activation of NFAT-CAT (Figure 2c ). In contrast, no NFAT-CAT activity was detected in PML(À/À) MEFs expressing NFATc or NFATp (Figure 2c ). The lack of NFAT transactivation in PML-deficient MEFs was NFAT specific; p65-mediated kB-CAT activation was not reduced in PML-null MEFs (Figure 2d) . A moderate but reproducible increase of kB-CAT activation was instead detected in the absence of PML. The inability of PML-null MEF to support NFAT transactivation was fully reversed by expression of wild-type PML. Figure 2e shows that the reintroduction of PML-VI into PML-deficient MEF restored the activation of NFAT-CAT mediated by NFATc, supporting the specificity of PML on NFAT transactivation.
Sumoylation of PML is involved in NFAT transactivation
We next evaluated whether PML promotion of NFAT transactivation requires PML sumoylation. The stimulatory effect of sumoylation-defective PML-VI (PMLDSUMO in 25), with mutation at the three sumoylation sites of PML (K65R, K160R and K490R), on NFAT transactivation in T cells was determined. PML-VIDSUMO failed to enhance NFAT-CAT activation stimulated by TPA/A23187 in ) and A23187 (80 ng ml
À1
) 24 h after transfection. CAT activities were determined 18 h after T-cell activation. For (d-f), each experiment was independently repeated twice, and displayed results are average of triplicates from the same experiment with standard deviation indicated.
Jurkat and EL4 cells (Figures 1e and f) . PML-VIDSUMO was also transfected into PML-null MEF to assess its ability to restore the activation of NFAT-CAT. In contrast to wild-type PML-VI expression, PML-VIDSUMO was ineffective in reconstituting the transactivation of NFATc (Figure 2e ). Therefore, sumoylation of PML is required for NFAT transactivation.
Promyelocytic leukemia has been shown to promote transcription activities by sequestering Daxx into PODs, a highly sumoylation-dependent process (Li et al., 2000; Lin et al., 2003 Lin et al., , 2004 . We thus examined whether the PML promotion of NFAT transactivation is due to removal of the inhibitory effect of Daxx by recruiting Daxx to PODs. Co-transfection of Daxx with NFATc only weakly interfered with the NFATc-directed reporter activation (Figure 2f ). It is thus unlikely the profound stimulatory effect of PML on NFAT activation could be attributed to the quenching of the small inhibitory activity imposed by Daxx. Daxx sequestration is probably not a major mechanism underlying the PML enhancement of NFAT activation. Recent studies reveal difference in specificity between different PML isoforms to interact with transcription regulators (Jensen et al., 2001; Condemine et al., 2006) . We tested the effect of PML isoforms PML-IV and PML-I on NFAT activation. In contrast to the promoting effect of PML-VI, PML-IV exhibited no effect on NFAT activation in 293 cells ( Figure 2g ) and PML-null MEFs (Figure 2h ). Another long form of PML, PML-I, increased NFAT-CAT activation in 293 cells (Figure 2i ) as well as in PML-deficient MEFs (data not shown). Therefore, different PML isoforms display distinct effect on NFAT transactivation: PML-I and PML-IV, but not PML-IV, promote NFAT activation.
PML interacts with NFAT in vitro and in vivo
We next evaluated possible NFATc-PML interaction by co-immunoprecipitation analysis. In 293 cells overexpressing both NFATc and PML-VI-myc, NFATc was brought down by immunoprecipitation of PML-VI-myc (Figure 3a) , suggesting a potential interaction between PML and NFATc. An interaction between the overexpressed PML-IV and NFATc was also detected (Figure 3b) . Similarly, transfected PML-I was coprecipitated with NFATc (Figure 3c ). The association between the endogenous PML and NFATc was then determined in T cells. NFATc was absent in unstimulated Jurkat cells, and was prominently induced 4 h after Immunoprecipitates were resolved on SDSpolyacrylamide gel electrophoresis (PAGE) and blotted with anti-PML or anti-NFATc. The amounts of NFATc and PML in the nuclear extracts were also assessed by immunoblots (Input). The major isoform of PML in EL4 is PML-I/II, while only PML-VI is shown for Jurkat cells. (f) Direct interaction between PML and NFATc by GST pull-down analysis. The left panel is a schematic illustration of NFATc mutants with deletion at different domains, marked by amino-acid residues. Aliquots of 2 mg of GST, GSTNFATc, GST-TAD, GST-NHR or GST-RSD were loaded onto glutathione agarose beads and incubated with 2 mg of PML-His. The amounts of PML-Myc pulled down by GSH-agarose were detected by anti-His antibodies.
T-cell stimulation (Figure 3d , input). In accordance with the NFATc expression, anti-PML, but not control immunoglobin, pulled down endogenous NFATc only in activated Jurkat cells. Similarly, immunoprecipitation of NFATc in activated EL4 cells brought down the dominant isoform of PML, PML-I/II, according to the molecular weight (Figure 3e ). These results demonstrate the association between NFATc and different PML isoform in vivo.
We further examined whether NFATc directly interacts with PML. Glutathione S-transferase (GST)-NFATc and its different domain deletion mutants, GST-TAD, GST-NHR and GST-RHD (Figure 3f ), were constructed. In a GST pull-down assay, PML-VIHis was brought down by GSH-agarose when the bacterially expressed GST-NFATc was co-incubated ( Figure 3f , GST-NFATc), illustrating a direct interaction between NFAT and PML-VI. GST-TAD, GST-NHR and GST-RSD were also used to elucidate the region on NFATc that interacts with PML. Neither the TAD nor the RSD domain of NFATc bound to PML (Figure 3f ). In contrast, GST-NHR pulled down PML-VI-His, indicating that the NHR domain is the PML-binding region on NFATc. We also examined the intracellular localization of endogenous NFATc and PML under confocal microscopy. PML nuclear bodies were clearly visible in Jurkat cells before stimulation, while NFATc was completely absent (Supplementary Figure 1A) . T-cell receptor activation led to appearance of NFATc speckles in most of the activated T cells (Supplementary Figures 1B and C) . Almost all NFATc speckles were co-localized with endogenous PML in the nucleus of activated Jurkat cells (Supplementary Figure 1D) .
The interaction of PML with NFAT led us to examine whether PML increases the overall nuclear retention of NFAT. Supplementary Figures 2A-C illustrate that the overexpression of PML-VI-myc did not apparently increase the nuclear contents of NFATc and NFATp in activated Jurkat or DO11.10T cells. We also determined the nuclear presence of NFAT when PML was knockdown in Jurkat cells. Supplementary Figure  2D shows that downregulation of PML weakly decreased the nuclear translocation of NFATp after T-cell activation. Similarly, T-cell receptor-stimulated NFATc nuclear localization was moderately reduced when PML was knockdown (Supplementary Figure 2E) . Therefore, even though PML overexpression did not increase the presence of NFATp and NFATc in nucleus, PML knockdown resulted in a small but clear decrease of NFAT nuclear localization.
PML is required for expression of many, but not all, NFAT-targeted genes We next examined whether the expression of NFATdependent genes involves PML. We used Jurkat cells with PML knockdown (Figure 2a ) to evaluate the expression of NFAT-dependent genes including TRAIL, Nur77, IL-2, FasL, Cbl-b and TNF-a. T-cell receptor activation led to upregulation of these genes in control Jurkat cells. Activation-induced expression of TRAIL, Nur77, IL-2, Cbl-b and TNF-a was attenuated in PMLknockdown Jurkat cells (Figures 4a-c) . However, not all NFAT-targeted gene expression was affected by PML downregulation. FasL, known to be NFAT-dependent (Latinis et al., 1997) , was induced to similar extents in control and PML-knockdown cells (Figure 4a) . We further used PML-deficient MEFs to delineate the contribution of PML to NFAT-directed gene expression. Introduction of either NFATc or PML into PMLnull MEFs led to expression of TNF-a transcript, which was further increased by co-expression of NFATc and PML (Figure 4d) . Reduction in the induced TNF-a and TRAIL mRNA in PML-knockdown Jurkat cells was more evident when measured by quantitative PCR (Figures 4e  and f) . Downregulation of PML resulted in decreased expression of TNF-a proteins when quantitated by ELISA (Figure 4g ). Immunoblots also confirmed the diminished expression of Nur77, TRAIL and Cbl-b proteins when PML was knockdown in Jurkat cells (Figures 4h and i) . Together, our results suggest that PML enhances expression of selective NFAT-directed genes.
Association of PML, NFAT and CBP on TNF-a and IL-2 promoters
We next determined whether NFAT-PML interaction was detectable on those PML-dependent gene promoters. In the nuclear extracts of activated Jurkat cells, biotinylated NFAT-binding elements from TNF-a promoter successfully pulled down NFATc as well as PML (Figure 5a ). We also used chromatin immunoprecipitation (ChIP) analysis to assess the association of PML on the promoter stimulated by NFAT and PML. In the nucleus of activated Jurkat cells, anti-NFATc, but not control immunoglobulin G, brought down NFAT-binding DNA element from IL-2 promoter (Figure 5b ). The same DNA sequence was pulled down by immunoprecipitation of PML or CBP, indicating the simultaneous presence of NFATc, PML and CBP. The recruitment of NFATc and CBP to NFAT-binding element was PML-dependent. In Jurkat cells with PML knockdown, neither NFATc nor CBP was associated with TNF-a promoter in ChIP analysis (Figure 5c ). To further delineate the interaction between PML and NFAT on the same promoter, immunoprecipitates containing NFATc were reprecipitated with antibody specific for PML. NFAT-binding DNA element was still brought down after reChIP analysis (Figure 5b) , supporting an interaction between PML and NFAT on the promoter with NFAT DNA-binding sequences.
Discussion
In this study, we illustrate a specific enhancement on NFAT-directed transcription by PML. NFAT transactivation was impaired in PML-knockdown Jurkat cells (Figure 2b ) and in PML-deficient MEFs (Figure 2c ). Reconstitution of PML restored the transcription activity of NFAT in PML-null MEFs (Figure 2e) . We also identified a specific interaction between PML and NFAT (Figure 3) . PML was found to associate with NFAT-binding DNA sequences on IL-2 and TNF-a promoters ( Figure 5) . PML is therefore a component of the NFAT transactivation complex.
We observed that the absence of PML led to a modest but clear increase in the transactivation of NF-kB p65 (RelA) (Figure 2d ), while overexpression of PML resulted in a weak inhibition of NF-kB activation (Figure 1d ). These are consistent with previous reports that PML represses the activation of RelA (Wu et al., 2003b) . NFAT is a member of the transcription factors belonging to Rel/NF-kB family. PML binds to the regulatory domain of NFAT (Figure 3) , while PML also interacts directly with RelA (Wu et al., 2003b) . Transactivation of NFAT and NF-kB are both CBP/ p300-dependent (Perkins et al., 1997; Garcia-Rodriguez and Rao, 1998), with CBP/p300 as components of PODs. With common properties shared by NFAT and RelA, the fact that binding of NFAT and RelA to PML leads to opposite effects on transactivation, therefore, is noteworthy.
The nuclear factor of activated T cell has a wide spectrum of target genes. There is selectivity among the NFAT-targeted genes for the involvement of PML in their expression, as shown by the requirement of PML for the expression of TRAIL, Nur77, IL-2, Cbl-b and TNF-a, but not FasL (Figure 4) . Previous studies on the regulation of p53 activity by PML (Fogal et al., 2000) have illustrated promoter specificity when PML enhances p53 transactivation, with only particular p53-dependent genes being stimulated by PML. A similar scenario is likely applied to the regulation of NFAT transactivation by PML. We are currently looking into the specificity of different NFAT-containing promoters in the context of PML-NFAT action. The selective activation of NFAT-dependent genes by PML may explain why phenotypes associated with NFAT-knockout mice are not found in PML-null mice. In addition, even for genes that are stimulated by PML, their gene products may still be subjected to negative regulation by PML. For example, while PML is required for Nur77 induction (Figure 4) , PML interacts directly with Nur77 to repress the transcription activity of Nur77 . The overall effect of PML on NFAT-targeted genes, therefore, is not necessary, simply stimulatory.
Promyelocytic leukemia interacts directly with CBP (Doucas et al., 1999) . PML nuclear bodies contain CBP/ p300 and RNA polymerase II, and are associated with high transcription activity (von Mikecz et al., 2000; Wang et al., 2004) . PML increases the transcription activity of p53, Myc and c-Jun by increasing CBP co-localization (Guo et al., 2000; Cairo et al., 2005; Salomoni et al., 2005) . In this study, NFATc was found co-localized with PODs (Supplementary Figure 1) . We further demonstrated that CBP recruitment was impaired in PMLknockdown cells on ChIP analysis (Figure 5 ), suggesting that PML is required for the efficient recruitment of CBP in vivo. Interestingly, NFAT is able to interact with CBP in vitro (Garcia-Rodriguez and Rao, 1998; Avots et al., 1999; Wu et al., 2003a) . The presence of PML or POD may thus provide the structural environment for NFAT to effectively bind to CBP. In addition, we also found that the nuclear presence of NFAT was moderately reduced in PML-downregulated cells (Supplementary Figures 2D and E) , suggesting that PML or POD stabilizes nucleus-situated NFAT. Therefore, the interaction of NFAT with PML may help to maintain the nuclear localization of NFAT and promote the recruitment of CBP, leading to an overall increase in NFAT transcription activity.
In GST pull-down assay, we illustrated a direct binding between NFATc and PML-VI (Figure 3f) . PML-VI, the smallest PML isoform localized in nucleus, is composed of exons 1-6 that are conserved in human PML-I, -II, -III, -IV and -V (Jensen et al., 2001) . The binding of NFAT to PML-VI thus suggests that NFAT should also bind to PML-I, -II, -III, -IV and -V. This was confirmed by the association of NFAT with PML-I or PML-IV in immunoprecipitation analysis (Figures 3b  and c) . In mouse thymoma EL4 cells, NFATc was also co-precipitated with PML-I/II, the dominant isoforms of PML in mouse (Figure 3d ). It may be noted that there are differences between mouse and human in the expression of PML isoforms. Only PML-I and PML-V are conserved between human and mouse, while analogs of human PML-II and PML-III do not exist in mouse (Condemine et al., 2006) . There are also functional discrepancies between mouse PML and human PML in the ability to promote major histocompatibility complex class I expression (Bruno et al., 2003) . However, as NFAT binds to the conserved region of human PML, with the 90% similarity between mouse PML-I and human PML-I in their functional domains (Goddard et al., 1995) , the coupling of NFAT activation to PML will be similar in mouse and human T cells. We have accordingly detected an enhancing effect of PML on NFAT activation in EL4 cells (Figures 1c, f and 2f) .
The binding of PML to NFAT, however, does not necessarily lead to elevated activation of NFAT. In contrast to PML-I and PML-VI, overexpression of PML-IV did not affect the transcription activity of NFAT (Figures 2g-i) . The exact mechanism underlying the differential effect between PML-I/-VI and PML-IV is at present unclear. PML-IV is known to interact with histone deacetylase to inhibit transcription (Wu et al., 2001) , whereas PML-VI does not recruit histone deacetylase (Li et al., 2000) . PML-IV is also the only PML isoform that induces premature senescence (Bischof et al., 2002) . Additionally, PML-IV is distinct from other PML isoforms for its ability to trigger c-Myc destabilization (Buschbeck et al., 2007) . Notably, even though all PML isoforms recruit p53 and CBP to PODs, PML-IV is the only isoform that increases p53 stability through inducing Ser-46 phosphorylation and Lys-382 acetylation on p53 (Bischof et al., 2002) . In addition, PML-IV, but not PML-III, binds to homeodomaininteracting protein kinase 2 (HIPK2) (Mo¨ller et al., 2003) . PML-IV is therefore distinct from other PML isoforms in several physiological activities. Whether the difference between PML-I/VI and PML-IV on NFAT transactivation could be attributed to histone deacetylase interaction, c-Myc repression, p53 modification or HIPK2 binding is currently being evaluated.
The coupling of NFAT-PML observed in this study may account for some of the physiological functions of PML. The promotion of NFAT-directed TNF-a expression by PML is consistent with the involvement of PML in antiviral responses. NFAT-dependent expression of TRAIL (Figure 4) likely plays a key role on IFN-a-induced apoptosis mediated by PML (Crowder et al., 2005) . Whether the requirement of PML in the expression of TRAIL and TNF-a is linked to the general proapoptotic functions of PML (Wang et al., 1998) is currently being evaluated. On the basis of PML-dependent expression of Cbl-b (Figure 5 ), the NFAT-targeted gene that regulates T cell anergy (Macian et al., 2002) , we are in the process of delineating the possibility that PML could be involved in immune tolerance. Further studies will help identify additional PML-dictated physiological events that involve NFAT.
Materials and methods
Reagents PML þ / þ and PMLÀ/À MEFs were gifts of Dr Gerd G Maul (Wistar Institute, Philadelphia), and were cultured in Dulbecco's modified Eagle's medium with 10% fetal calf serum as described (Ishov et al., 2004) . Human NFATc was a gift of Dr Gerald Crabtree (Stanford University, Stanford, CA, USA) and was obtained through Dr Hsiou-Chi Liou (Cornell University Medical College, New York, NY, USA). NFATp was a gift of Dr Anjana Rao (Harvard Medical School, Boston, MA, USA). pCMX-PML-VI was a gift of Dr Ron Evans (Salk Institute, San Diego, CA, USA). The generation of pCMX-PML-VIDSUMO, with mutation of K65R, K160R and K490R, has been previously described (Lin et al., 2003) . Human PML-IV cDNA was a gift of Dr Kun-Sang Chang (MD Anderson Cancer Center, Houston, TX, USA). Human PML-I cDNA was purchased from GeneCopoeia (Germantown, MD, USA).
Transfection and CAT assays
For transfection of EL4 and Jurkat cells (5 Â 10 6 cells) T cells were washed, mixed with plasmid DNA in a volume of 400 ml OPTI-MEM (Gibco-Invitrogen, Carlsbad, CA, USA), and electroporated on a Bio-Rad Gene Pulser II (250 V and 975 mF for Jurkat cells, 280 V and 975 mF for EL4 cells). 293T cells were transfected using the calcium phosphate method. Transfection of MEFs was performed with FuGENE 6 transfection reagent (Roche, Mannheim, Germany). The transfection efficiency was determined 24 h after transfection by counting the fraction of green fluorescence cells. Jurkat cells were stimulated with TPA (50 ng ml
À1
) and A23187 (250 ng ml
) 48 h after transfection, while EL4 cells received TPA (10 ng ml
) and A23187 (80 ng ml
) 24 h after transfection. CAT activities were determined 18 h after T-cell activation. The CAT activities were measured as described (Ho et al., 1997) and normalized with the transfection efficiency. Each CAT experiment was independently repeated at least twice, and quoted results are average of triplicates in the same experiment with standard deviation indicated.
PML knockdown PML knockdown lentiviral construct was generated by subcloning PML-specific siRNA sequence into pLentiLox vector (pLL3.7). The target sequence was 5 0 -GAGTCGGCC GACTTCTGGT-3 0 . Lentiviruses were harvested from culture supernatant of 293FT cells transfected with 20 mg pLL3.7 or pLL3.7-PMLsiRNA, 15 mg psPAX2 and 6 mg pMD2.G. Jurkat cells were infected with recombinant lentivirus, and GFPexpressing cells isolated by fluorescence sorting 48 h later. The levels of PML were confirmed by immunoblots.
Real-time PCR
Total RNA (5 mg) was reverse transcribed in a total volume of 20 ml using MMLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA) and oligodT. PCR was performed using 10 ng equivalent of RNA in duplicates on an ABI7500 (Applied Biosystems, Foster City, CA, USA). Master mix and target probes specific for TRAIL (Hsoo234356_ml), TNF-a (Hs00174128_ml) and glyceraldehyde-3-phosphate dehydrogenase (Hs99999905_ml) were purchased from Applied Biosystems. The CT value of each gene was calculated using an ABI Sequence Detection System 1.31 Program and normalized against the mRNA levels of glyceraldehyde-3-phosphate dehydrogenase.
GST pull-down assay GST-NFATc (NFATc 1-706), GST-transactivation domain (TAD) (NFATc 1-106), GST-NFAT-homology region (NHR) (NFATc 107-425) and GST-Rel-similarity domain (RSD) (NFATc 426-716) were generated by subcloning NFATc and its mutants into pGEX-4T3 (Amersham Pharmacia, Buckinghamshire, UK). Recombinant GST fusion proteins were then purified on GSH agarose. Recombinant PML-His 6 was then purified on Ni-NTA agarose (Qiagen, Hilden, Germany). Cell lysates for GST pull-down assays were prepared in GSH binding buffer (50 mM potassium phosphate buffer, pH 7.5, 150 mM KCl, 1 mM MgCl 2 , 10% glycerol, 1% Triton X-100, 1% aprotinin and 1 mM phenylmethylsulfonyl fluoride). GST fusion protein (2 mg) (GST-NFATc or its mutants) was loaded on to GSH agarose (30 ml, 50% slurry), and incubated with 2 mg of PML-His 6 overnight at 4 1C. GST agarose beads were then washed three times with binding buffer, and resolved by SDS-polyacrylamide gel electrophoresis, and the captured PML-His was detected by anti-His (H-3, Santa Cruz Inc., Santa Cruz, CA, USA).
DNA affinity precipitation assay DNA affinity precipitation assay was performed according to Zhu et al. (2002) with modification. Nuclear extracts were purified from Jurkat cells stimulated with or without TPA (50 ng ml À1 )/A23187 (250 ng ml
À1
) stimulation for 4 h. The binding assay was performed by mixing 100 mg of nuclear extract proteins with 2 mg of biotinylated-specific NFATbinding oligonucleotides in a final 400 ml of binding buffer (20 mM Tris-HCl (pH 7.9), 10% glycerol, 1 mM EDTA, 5 mM MgCl 2 , 0.1% NP-40, 0.1 M NaCl, 0.1 mM DTT and protease inhibitor cocktail (Roche)) and incubated at room temperature for 40 min. Streptavidin-agarose beads (20 ml) were then added, and samples were incubated at 4 1C for one additional hour with rotation. Agarose beads were collected by centrifugation, and washed three times with cold phosphate-buffered saline containing 0.5% Triton X-100. The binding proteins were eluted with SDS loading buffer and separated on SDSpolyacrylamide gel electrophoresis, followed by western blot with specific antibodies. 5 0 -biotinylated NFAT-binding oligonucleotides were correlated to the TNF-a promoter k3 site (sequence: 5 0 -biotin-CAG-ATG-AGC-TCA-TGG-GTT-TCT-CCA-CCA).
ChIP and Re-ChIP
ChIP and Re-ChIP were conducted with modification from Metivier et al. (2003) . The detailed procedures for ChIP and Re-ChIP are described in Supplementary Methods.
